In its 2026 second quarter filing, BioScience Health Innovations, Inc. (BHIC) detailed a deliberate 'preparation-for-scale' phase emphasizing supply chain strengthening, vendor qualification, and ERP system upgrades. The company markets proprietary nutraceutical products, including a patent-pending NAD+ cellular health formulation and clinically documented testosterone optimizer, through multi-channel sales including direct-to-consumer subscription and wholesale. BHIC’s transition from OTC to senior exchange status and international market pursuits reflect strategic efforts to enhance liquidity and distribution breadth. However, capital constraints and OTC penny-stock liquidity remain salient risks that may impact growth execution.